Personalised Medicine* is attracting serious attention at many levels internationally. The paper discusses personalised medicine, the future of genomics, current challenges, impact of genomics on the insurance industry and recommendations for actuaries.
Christelle Dieudonné, Chair of the Health Committee, said, “Personalized medicine and knowledge of genomics poses a challenge for the insurance industry in the areas such as product innovation, tariffs and risk management. As a risk or opportunity, this evolution can have an impact on the role of health actuaries around the world. We hope this paper will provide useful information to actuaries on the risks associated with personalised medicine and the key issues to be considered.”
The paper is available on the IAA website under PUBLICATIONS/PAPERS
This activity supports the IAA’s mission to promote the role, reputation and recognition of the actuarial profession. Further, it contributes towards achieving the IAA’s strategic objective to facilitate the coordination, use and expansion of the scientific knowledge and skills of the actuarial profession, to help enhance the scope, availability, and quality of actuarial services offered by individual members of its member associations.
To learn more about the work of the IAA on this topic, contact the Secretariat, care of the Health Committee Chairperson.
* Personalised medicine tailors medical treatment to the individual characteristics of each patient.